Oxford Cannabinoid Technologies Holdings plc

("OCTP" or the "Company")

Notice of General Meeting

&

Posting of Circular

Oxford Cannabinoid Technologies Holdings plc (LSE:OCTP), the biotech company developing prescription cannabinoid medicines, announces that it will today be posting a circular (the "Circular") together with a form of proxy ("Proxy") to Shareholders convening a general meeting (the "General Meeting").

The General Meeting is being called to approve a special resolution in respect of the Company's authority to disapply pre-emption rights in relation to any conversions under the convertible loan note agreements which the Company referred to in its announcement of Tuesday 30 January 2024 and which were entered into and announced earlier today. For further details shareholders should refer to the announcement released today entitled 'Convertible Loan Note Agreements'.

Both the Circular and the Proxy will shortly be uploaded to the National Storage Mechanism and will be available at: www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism.

These documents are also available on the Company's website at: https://www.oxcantech.com/investors and in hard copy to shareholders upon request to the Company Secretary at Prama House, 267 Banbury Road, Oxford, England, OX2 7HT.

The Company's General Meeting will be held at the offices of Penningtons Manches Cooper LLP at 125 Wood Street, London EC2V 7AW on 19 February 2024 at 11.00 a.m.

The Company is aware that the General Meeting gives shareholders the opportunity to ask the Board questions and encourages shareholders to submit any such questions in advance via email to the Company Secretary Rob Bennett at rob@oxcantech.com. Answers to questions received will, where appropriate, be uploaded onto the Company website following the General Meeting.

The Directors of the Company accept responsibility for the content of this announcement.

Enquiries:

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the holding company of Oxford Cannabinoid Technologies Ltd (together the "Group"), a pharmaceutical Group developing prescription cannabinoid medicines initially targeting the US$ multi-billion global pain market.

OCTP currently has a portfolio of four drug development programmes. Its lead compound, OCT461201, will initially target neuropathic and visceral pain (including irritable bowel syndrome ("IBS") and chemotherapy induced peripheral neuropathy ("CIPN"). The global market for CIPN alone is currently forecast to reach US$1.17bn by 2028.

OCTP's drug development pipeline comprises both natural and synthetic compounds, and includes compounds targeting trigeminal neuralgia, a severe type of face pain, and cannabinoid derivatives targeting pain and potentially other therapeutic areas. Having established an exclusive licence agreement with Canopy Growth Corporation for their entire pharmaceutical cannabinoid derivative library, OCTP now has a portfolio of almost five hundred derivatives and intellectual property rights including fourteen patent families and associated research data.

OCTP has a clearly defined path to commercialisation, revenues and growth. The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence. OCTP's portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities.